Septerna, Inc. appoints Gil Labrucherie as CFO to advance GPCR drug discovery and expand its therapeutic pipeline.
Quiver AI Summary
Septerna, Inc., a clinical-stage biotech firm focused on G protein-coupled receptor (GPCR) drug discovery, has appointed Gil Labrucherie as its new Chief Financial Officer. Labrucherie brings over 25 years of experience in finance and legal roles within the biopharma sector, having previously served as CFO and Chief Business Officer at ACELYRIN, and held senior positions at Nektar Therapeutics. His extensive expertise in public finance and capital strategy will support Septerna's growth, particularly in advancing its oral small molecule GPCR programs and the Native Complex Platform™. Labrucherie expressed enthusiasm for joining Septerna at a crucial time in the company's development and aims to contribute to transformative therapeutic opportunities.
Potential Positives
- Appointment of a seasoned executive: The hiring of Gil Labrucherie, a professional with over 25 years of experience in finance and legal roles in the biopharma sector, enhances the leadership team.
- Expertise in capital raising: Mr. Labrucherie has a proven track record, having raised over $1.5 billion in equity capital, which could benefit Septerna's financial strategy and support the advancement of its pipeline.
- Focus on innovation and growth: The press release emphasizes Septerna's commitment to scaling its organization and advancing its drug discovery platform, suggesting a proactive approach to growth and development in the biopharmaceutical industry.
Potential Negatives
- Appointment of a new CFO may indicate potential instability or previous management issues, suggesting the company needed to make a significant leadership change.
- Reliance on the new CFO's extensive financing experience could imply ongoing financial challenges or the need for strategic alignment within the company.
- The description of the CEO's excitement suggests that the company has not yet achieved significant milestones, raising concerns about current performance and future prospects.
FAQ
Who has been appointed as the Chief Financial Officer of Septerna, Inc.?
Gil Labrucherie has been appointed as the Chief Financial Officer of Septerna, Inc.
What experience does Gil Labrucherie bring to Septerna?
He has over 25 years of leadership experience in finance and legal roles within public biopharmaceutical and technology companies.
What is Septerna, Inc. focused on?
Septerna, Inc. is focused on pioneering GPCR drug discovery and developing innovative therapies using its Native Complex Platform™.
What previous roles did Gil Labrucherie hold before Septerna?
He served as CFO and CBO at ACELYRIN and held key roles at Nektar Therapeutics and other high-growth tech companies.
What therapeutic areas does Septerna's pipeline target?
Septerna's pipeline targets endocrinology, immunology and inflammation, and metabolic diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SEPN Insider Trading Activity
$SEPN insiders have traded $SEPN stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SEPN stock by insiders over the last 6 months:
- ROCK VENTURES V, L.P. THIRD has traded it 2 times. They made 2 purchases, buying 650,000 shares and 0 sales.
- CAPITAL MANAGEMENT, L.P. RA has traded it 2 times. They made 2 purchases, buying 4,170,000 shares and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Full Release
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies.
“We are excited to welcome Gil to the team,” said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. “His extensive expertise leading public company finance and capital strategy will be instrumental as we continue scaling our organization with the advancement of SEP-786 and our broader pipeline of oral small molecule GPCR programs, and expand the applications of our Native Complex Platform™.”
“This is an extraordinary moment to join Septerna and help realize its pioneering vision of unlocking the full potential of GPCRs,” said Mr. Labrucherie. “The company’s diverse portfolio of assets, each with significant therapeutic and market potential, and its cutting-edge platform for rapid, sustainable drug discovery and development, position Septerna at the forefront of innovation. I am honored to join this world-class team and am eager to contribute to the advancement of multiple transformative therapeutic opportunities to improve patients’ lives.”
Mr. Labrucherie most recently served as Chief Financial Officer and Chief Business Officer at ACELYRIN, where he led the company’s finance, accounting, investor relations and corporate communications, and business development organizations. Before that, he served as Chief Financial Officer and Chief Operating Officer of Nektar Therapeutics, where he led financial accounting and public reporting, business and strategic planning, corporate legal, intellectual property, government affairs, information technology and supply chain management, and previously served as Nektar’s Senior Vice President and General Counsel. Earlier in his career, Mr. Labrucherie held executive leadership positions at various high-growth technology companies, and he began his career as a corporate associate at Wilson Sonsini Goodrich & Rosati. Over the course of his career, Mr. Labrucherie has raised more than $1.5 billion in private and public equity capital and helped generate more than $1 billion in realized value from strategic partnering transactions. He currently serves on the board of Rezolute, Inc.
Mr. Labrucherie holds a J.D. from the University of California Berkeley School of Law, a B.A. from the University of California Davis, and is a CFA charterholder and a member of the State Bar of California.
About Septerna
Septerna, Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of its deep pipeline of oral small molecule product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Septerna was launched by preeminent drug discovery company builders and scientific leaders in the biochemistry, structural biology, and pharmacology of GPCRs. For more information, please visit
www.septerna.com
.
Investor Contact:
Renee Leck
THRUST Strategic Communications
[email protected]
Media Contact:
Carly Scaduto
Carly Scaduto Consulting
[email protected]
